Field Medical by Steven Mickelsen has gone on to raise yet another $35 million in investment in order to advance the preparations for its very important trial that studies pulsed field ablation in order to treat ventricular tachycardia.
It is worth noting that the series B financing round happened to be led by BioStar Capital as well as Cue Growth and also saw participation from the present strategic investors.
Significantly, Mickelsen happens to be the electrophysiologist who invented the Farapulse PFA system, which is now helping change how atrial fibrillation gets treated and also driving fast growth when it comes to Boston Scientific. It is well to be noted that after Boston Scientific went on to acquire Farapulse, Mickelsen founded Field Medical in 2022 in order to focus on pulsed field ablation approach development when it comes to ventricular tachycardia, which is an irregular heart rhythm that can lead to sudden death.
Apparently, physicians have gone on to embrace pulsed field ablation so as to treat AFib, which is a common arrhythmia that raises the risk of stroke, ever since Medtronic and Boston Scientific brought in the first system to the market in the US sometime in late 2023 and early 2024.
This technology goes on to offer a potentially safer option to ablate the cardiac tissue, which is the root cause of abnormal heart rhythm, by decreasing the risk of harm to the esophagus, and it can also be a faster procedure as compared to the traditional ablation methods. Interestingly, Johnson & Johnson also happens to sell a pulsed field ablation device, while Abbott anticipates the Food and Drug Administration to give its Volt system approval in 2026. Based in California’s Cardiff by the Sea, Field Medical is looking forward to expanding its treatment choices for patients who happen to have ventricular tachycardia by designing a PFA system, which targets this condition.
According to Mickelsen, who is the CEO of Field Medical, ventricular tachycardia happens to be among the most underrated segments when it comes to electrophysiology; still, physicians lack the tools that they require. What is really exciting, according to him, is how VT happens to be mirroring the early days of the AFib market.
As a matter of fact, the existing technology does not meet the present clinical demand, as per the company.
According to the physician and the founder as well as the senior managing director of BioStar Capital, Louis Cannon, the fact is that Field Medical’s technology happens to be doing what few companies don’t do – tackling one of the most challenging and under-addressed issues within cardiology with real urgency as well as innovation. The physician-led team happens to bring the right insight, and their FieldForce platform puts forth the right tools. He added that they are indeed proud to support this next chapter as they move much closer to transforming VT care.
It is well to be noted that the latest financing of the company follows a $40 million round in April 2025, bringing the total funds that have been reached to date to $75 million. Apparently, the new funds are going to support the start of the very important Veritas Trial, which will further the development when it comes to the FieldForce system and also broaden the clinical and regulatory capacities of the company.
